A healthcare-focused venture investment fund with a team who are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China, has past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.
The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.
The firm has no specific management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A venture capital firm based in the USA invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.
The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.
The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A venture capital firm with China headquarters and additional USA office is investing from its US$200 million fund with a focus on high-tech enterprises in China and Western countries. The firmseeks to invest in innovative enterprises in sectors including: biomedicine, medical devices, healthcare and bio-tech. Typical equity investments range from $1-6 million in Angel, Series A and B rounds. The firm is looking for opportunities in China, the US and Canada.
Within healthcare, the firm considers biomedicine, medical devices, and healthcare IT. The firm is most interested in personalized medicine products with an angle to the China market. Within healthcare IT, the firm prefers home-care, consumer, or physician-patient interface products. The firm considers products from Angel Round to Series B.
The firm is looking for competent management teams. The firm may request distribution rights on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A family office based in East Coast USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.
The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.
The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
RESI’s partnering platform is unique in its ability to filter and sort through investor and company profiles, allowing both companies and investors to find partners who are match for them. The partnering system increases the value for attendees participating in our events, eliminating wasted meetings discovering that you are not a fit for each other.
As an example, one of our fundraising CEOs, who has a blood-based technology in an orphan indication, asked us to look up investors who are interested in diseases affecting the blood, in combination with those investing in orphan diseases. At this up and coming Digital RESI event next week we found that of the 250 investors that 141 will look at investing in therapeutics treating diseases of the blood, presenting a terrific opportunity to connect with quite a few investors interested in that space. But there are subtleties here, because investors come in several flavors: those who are very specific in their investment interests, of which we found 37, and those who are opportunistic, 104 investors who seek compelling technology and look more broadly at the early technology assets that surface on their radar screen.
However, the benefit to companies improves greatly by employing the LSN Investor database in addition to participation in RESI events. Doing the same search in the Investor Platform yields 1439 investors interested in therapeutics treating blood diseases. It is even possible to narrow that down further, with a result of 311 investors that are interested in therapeutics treating orphan blood disorders. This kind of granularity is what makes LSN’s services so powerful, and so useful.
By Claire Jeong, Vice President of Investor Research, Asia BD, LSN
As many readers know, LSN organized its inaugural digital RESI “Europe” conference last month. RESI had a digital agenda in place, which included various panels & workshops, Innovation Challenge finalists, and Featured Company Pitch Sessions. One of the panels LSN organized was “Big Pharma”, a popular session that is included at almost every RESI conference.
Large pharmaceuticals continue to play a key role in the early-stage biotech ecosystem by actively scouting and fostering external innovation, orchestrating various types of partnership models to work with novel science. Last year, there were notable partnerships such as Gilead’s deal with Goldfinch Bio for their kidney disease pipeline, or Roche’s deal with Skyhawk Therapeutics for developing small molecule therapies that modulate RNA splicing, in CNS and oncology. For an emerging startup, the implications of partnering with global pharma are tremendous and they are always highly sought after at RESI.
So how can people successfully engage with global, large pharmaceutical groups? For many companies, the entire process may seem daunting. The Big Pharma panel organized at the last RESI covered perspectives of various organizations, represented by the following panelists:
Arpita Maiti, Executive Director & Global Head, Inflammation & Immunology, ES&I,Pfizer
Chris Church, Manager, Search & Evaluation, CVRM, AstraZeneca
Mark Day, VP Research & Emerging Sciences, Otsuka Pharmaceuticals
Elena Ritsou, Global Head Oncology Business Development, Ipsen S.A.
Some key takeaways:
Having the whole package – great science, management team, supporting materials. All groups really are open to companies of all stages of development, as long as the science they are working on is compelling. Most of the represented groups are open to considering various types of modalities, while Ipsen has more focused interests, mainly focusing on small molecule therapeutics. Some groups delved into more specific technology areas of interest, such as Pfizer’s expertise and research into nanoparticles and AstraZeneca’s interest in technologies that increase oral bioavailability of peptides.
As long as the company is supported by a clear and well-organized pitch deck and other supplementary materials, you can expect a positive initial response. It is also important to note that pharmaceuticals want to work with management teams who are willing to listen and adapt to their constructive feedback, meeting suggested timelines, etc.
Identify the right people to reach out to. Business units are organized based on therapeutic area. Colleagues who are responsible for business development and external research/collaboration attend many partnering conferences beyond BIO and JPM. Of course, pharma also regularly participate in major scientific conferences such as AACR, so it is not difficult to find a representative from a pharma you are seeking to engage. Main communication is done through e-mail, so you can e-mail a contact you have recently met at a networking event or conference, or start a new outreach by navigating through the pharma’s partnering webpage.
Try to identify the right person to contact, instead of reaching out to the CEO or key senior executives from the start (unfortunately, this seems to happen more often than it should). Even if you do reach out them, the opportunity will trickle down to the appropriate business unit, not only making this an inefficient process for everyone involved but also leaving a bad impression. Arpita from Pfizer mentioned that it would take 1-2 weeks to get back, which sounds like a standard timeline for others as well.
Understanding creative partnership & collaboration models. Global pharmaceuticals are all taking novel approaches to identify and support early-stage technologies, and they value the importance of open collaboration. It would be a good idea to properly research into the big pharma partners with whom you are most keen to establish better connections. Many pharmaceuticals have established corporate venture funds to invest in technologies that have synergies with the pharma’s current R&D pipeline. On this panel, every pharma has their own venture funding platform with the exception of AstraZeneca. Other approaches can include partnering with existing assets in pharma’s platform and engaging in a research collaboration or non-dilutive funding-type of deal, option-type agreements, etc. An example is Pfizer’s Centers for Therapeutic Innovation (CTI), through which Pfizer collaborates with investigators and academia to accelerate promising research.
So when is an opportunity “too early”? There is no absolutely right answer to this question, as people have different perspectives in evaluating opportunities. But, most can agree on the fact that when an early-stage opportunity is dismissed and comes back later when there has been further clinical development, the deal will become more expensive and complicated to negotiate. Mark from Otsuka noted that simply telling companies to come back when they have proof of concept or better data is just an easy way out. If he identifies a compelling opportunity, he will find someone else in the company who could share the excitement and build a case. Elena from Ipsen mentioned that, as they have ceased in-house research in oncology and rare disease, they tend to partner with and have the capacity to engage at the candidate development stage. They don’t shy away from the earliest stage opportunities, engaging in option-type agreements and supporting companies during this period to get them to candidate development stage and beyond (i.e. in-licensing).
By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN
The all-digital format is changing the way companies are showcasing themselves and drawing attention investors that are a fit for their stage development and product. RESI offers an inexpensive and compelling way to gain exposure via its Featured Company Forum. A company can enhance their global footprint by putting up their company information on a dedicated landing page. This Featured Company Page can host a video, Executive Summary, PowerPoint, Poster Board or Tear Sheet which can easy be found by an interested potential partner.
Each logo will be clickable so attendees can view the Featured Company’s dedicated pages. There will also be a link on each Featured Company page that enables attendees to quickly request a meeting with the company on the RESI Partnering Platform. LSN wanted to dedicate space at Digital RESI to feature early stage life science companies in order to give regional-based firms some global reach at events that are bringing global investors and strategic partners seeking technology assets. Think of it…global reach from your home office!
